AZD-1305 is a novel anti-arrhythmic compound that primarily blocks the fast component of IKr, l-type calcium currents and intra-ward sodium currents in mammalian cells and ventricular cardiomyocytes and can be used in studies to reverse arrhythmias.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:25 mg/mL (57.54 mM)

Inalate:4.3 microM, Inapeak:66 microM

AZD1305 (0.1–30 µM, n = 6, each concentration applied for 3 min ; dog cardiomyocytes) concentration-dependently blocked INalate (IC50=4.3 microM) and INapeak (IC50=66 microM). In PFs, E-4031, but not AZD1305, markedly prolonged APD90 (from 380+/-15 to 597+/-86 ms, P<0.05) after the long CL and augmented APD90 instability (2+/-0.4 to 24+/-6.1 ms, P<0.05), increases significantly attenuated by AZD1305 and lidocaine.[3]

AZD1305 ((36g/kg/min intravenously for 30 minutes ; anesthetized mongrel dogs) respectively increased QT and RR intervals from 290±7 to 397±15 ms (+37%, P<0.0001) and from 603±22 to 778±32 ms (+29%, P=0.002) at normal sinus rhythm. AZD1305 increased the QT interval from 535±28 to 747±36 ms (+40%, P<0.0001). AZD1305 slightly slowed the idioventricular rhythm.[2]